A statistically significant improvement was demonstrated in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer. It is first phase 3 Vectibix trial
The company is now allowed to use Opdivo in combination with Yervoy (ipilimumab) to treat unresectable or metastatic melanoma across BRAF mutational status. The indication includes both BRAF-wild
In a declaration signed by 85 companies and nine industry associations across 18 countries, they urged governments and industry to work in parallel in the development of new
The company is developing ALKS 5461, a once-daily, oral medicine to treat major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical
The agency approved Kyprolis in combination with dexamethasone or with lenalidomide plus dexamethasone to treat patients with relapsed or refractory multiple myeloma who have received one to three
Under the bestPWS ZAF-311 double-blind, placebo-controlled phase 3 trial, the company evaluated the safety and efficacy of beloranib in patients with Prader-Willi syndrome (PWS) in a six-month randomized
Arhalofenate is a novel dual-acting product candidate for the treatment of gout that lowers serum uric acid (sUA) and reduces gout flares. It inhibits a renal uric acid
The European Commission (EC) approved Entresto in November 2015 to treat adult patients with symptomatic chronic heart failure with reduced ejection fraction (HfrEF). Entresto performs the mechanism of
In November last year, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval for Oncaspar. Baxalta said the EC’s marketing
Biotie is primarily focused on developing therapeutics for central nervous system disorders. The company develops products for neurodegenerative and psychiatric disorders such as Parkinson’s disease, Alzheimer’s disease and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.